Home Cart Sign in  
Chemical Structure| 1464151-33-4 Chemical Structure| 1464151-33-4

Structure of Tinodasertib
CAS No.: 1464151-33-4

Chemical Structure| 1464151-33-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ETC-206 is a selective MNK1 and MNK2 inhibitor with IC50s of 64 nM and 86 nM, respectively.

Synonyms: Etc-206; AUM 001; ETC-1907206

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tinodasertib

CAS No. :1464151-33-4
Formula : C25H20N4O2
M.W : 408.45
SMILES Code : N#CC1=CC=C(C2=CN=C3C=CC(C4=CC=C(C(N5CCOCC5)=O)C=C4)=CN32)C=C1
Synonyms :
Etc-206; AUM 001; ETC-1907206
MDL No. :MFCD31692387
InChI Key :FWRFPHJSGLYXTD-UHFFFAOYSA-N
Pubchem ID :71766360

Safety of Tinodasertib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Tinodasertib

MAPK

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03414450 Ph+ Acute Lymphoblastic Leukem... More >>ia (Ph+ALL) Ph- Acute Lymphoblastic Leukemia (Ph-ALL) Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+) Chronic Myeloid Leukemia Blast Crisis (CML-BC, Ph+) Less << Phase 1 Withdrawn(Withdrawal requested... More >> by D3) Less << February 2023 United States, Georgia ... More >> Winship Cancer Institute, Emory University Atlanta, Georgia, United States, 30322 United States, Maryland The Center for Cancer and Blood Disorders Bethesda, Maryland, United States, 20874 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, Oregon Oregon Health & Science University Portland, Oregon, United States, 97239 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Singapore Singapore General Hospital Singapore, Singapore, 169608 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.45mL

0.49mL

0.24mL

12.24mL

2.45mL

1.22mL

24.48mL

4.90mL

2.45mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories